Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Insights From Global Key Opinion Leaders on Regional Regulatory and Guideline Nuances to Optimize Melanoma Management
Hussein Tawbi, MD, PhD
Emerging and Practice Changing Data in Immunotherapy Strategies for Melanoma
Data Driving Preferred Guideline Recommendations in First-Line Therapy for Metastatic Melanoma
Community Clinic: Translating Data Into Action ─ Practical Strategies for Optimizing First-Line RCC Management
Robert J. Motzer, MD
Elizabeth R. Plimack, MD, MS, FASCO
HER2 in Bladder Cancer: Breaking Through the Molecular Frontier
Vadim S. Koshkin, MD
Chairperson's Perspective: Innovative Approaches to IBS-C: Personalized Treatment for Better Outcomes
Darren Brenner, MD
Expert Perspectives From AUA 2025: Contextualizing the Evolving Landscape of Bladder Cancer
Neal Shore, MD, FACS
Sarah Psutka, MD, MS
New Strategies for Individualizing Treatment in DME
Luis A. Gonzalez, MD, MPH
Jeremiah Brown Jr., MD, MS, FASRS
From Doctor-Speak to Patient-Speak: Bridging the Communication Gap
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
Marilyn Yuanxin Ma Bui, MD, PhD
Anne Vincent-Salomon, MD
Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology
Vera Bril, MD
Nicholas J. Silvestri, MD
Hans Katzberg, MD
A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained
Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection
Jonathan Strober, MD
Living with gMG: Navigating Personal, Professional, and Mental Health Challenges
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.